I kliniske undersøgelser hos patienter med massive tumorer (inklusive bryst - og ovariecancer), som samtidig har fået cyclophosphamid eller taxaner, sås ingen yderligere toksiciteter.
During clinical trials in patients with solid tumours (including breast and ovarian cancer) who have received concomitant cyclophosphamide or taxanes, no new additive toxicities were noted.